Business Standard

Dr. Gurpreet Sandhu, President, Council for Healthcare and Pharma, Hails the Pfizer (Upjohn)- Mylan Merger to Form a New Generics Company


Press Trust of India NEW DELHI
/ -- Speaking of the merger of Pfizer's out of patent business (Upjohn) and Mylan that will lead to the formation of a yet to be named new company, Dr. Gurpreet Sandhu, President, Council for Healthcare and Pharma (CHP), said, "The Pfizer (Upjohn)-Mylan newco when formed, has the inherent potential to harness significant complementarities. The new order is all about capturing synergies. This becomes all the more important in the current environment of price reductions, efforts at cost control and the urgency to realise the goal of Universal Healthcare. The combine will bring together huge manufacturing capabilities in India, China, the US and other countries; a large portfolio of generics with a strong pipeline to comprehensively address most disease segments, a well-diversified geographical presence with 75% of sales outside the USA, extremely relevant to address the challenges of most under developed and emerging health systems, in addition to the mature ones.
"At the recently concluded legislative day meetings at the Capitol Hill, D.C, we at the Council for Healthcare and Pharmaceutical had stressed the urgent need to harness global synergies in pharmaceuticals and healthcare, so industry can manufacture high quality generic medicines where best feasible, make them available freely, where most required and at prices that increase access. Research, Manufacturing and Supply chains need to be synergised across industry, to meet these goals and I think the combination is well placed to achieve them."

The Council for Healthcare and Pharma (CHP) is an integrated, not-for-profit, global think tank that advocates the development of sustainable health systems around the World. It looks at engaging with Governments and other stakeholders to adopt rational approaches that capture benefits, that accrue through the optimization of the eco-system and value chain involved in treating diseases and keeping people healthy. CHP members includes domestic and global Pharmaceutical companies, Providers of Diagnostics, Medical device Manufacturers, Hospitals and adjunct services.
Headquartered in New Delhi, India, the Council focuses on Africa, Brazil, China, France, Germany, India, Japan, UK and the USA. Its important areas of work are in ease-of-doing business; increasing competitiveness; broadening access to safe, efficacious and affordable healthcare services and medicines. CHP is guided in its work by expert advisory committee's in Intellectual Property; Market Access; Regulatory Policy; Key Therapeutics - Women's Health, Oncology & Tropical Diseases; Research & Development (R&D) and Artificial Intelligence (AI); Environment; and Healthcare start-ups.
As a significant and credible stakeholder in alleviating the burden of disease, the CHP brings to bear the collective wisdom of industry and policy makers on health issues that stand to make a positive contribution to society in bringing about Universal healthcare.
Logo -

Disclaimer: No Business Standard Journalist was involved in creation of this content

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jul 30 2019 | 4:56 PM IST

Explore News